Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease. [PDF]
Yang X +6 more
europepmc +1 more source
Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update and Review with Insights from MPN Asia 2026. [PDF]
Abu-Zeinah G +18 more
europepmc +1 more source
Neutrophil-to-lymphocyte ratio as a gene-specific biomarker of JAK2-driven inflammation across CHIP and myeloproliferative neoplasms. [PDF]
Barbui T.
europepmc +1 more source
Glucose transport dependency defines a therapeutic vulnerability in JAK2V617F-driven myeloproliferative neoplasms. [PDF]
Weiand P +12 more
europepmc +1 more source
Collagen Turnover Is Associated with Disease Severity, Bone Marrow Fibrosis, and the <i>JAK2V617F</i> Variant Allele Frequency in Myeloproliferative Neoplasms. [PDF]
Bistrup CN +8 more
europepmc +1 more source
Single-cell long-read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML. [PDF]
Grabek J +15 more
europepmc +1 more source
JAK2<sup>V617F</sup>-positive clonal hematopoiesis in germline BRCA1 versus BRCA2 mutation carriers. [PDF]
Rodriguez MJ +15 more
europepmc +1 more source
Mathematical modeling of <i>JAK2V617F</i> clonal expansion in a general population cohort. [PDF]
Snyder J +11 more
europepmc +1 more source
Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.
Uchida T +13 more
europepmc +1 more source
Complete Hematological Response Coupled with Molecular Response in Polycythemia Vera Treatment with Ropeginterferon Alfa-2b. [PDF]
Vecchio V, Cacciola R, Cacciola E.
europepmc +1 more source

